AstraZeneca plc (ADR)

British drugmaker AstraZeneca <AZN.L> forecast revenue growth for this year of around 10% on Friday, as it factored in a hit from the coronavirus outbreak in China and fell short of analysts' expectations for fourth-quarter results.

AstraZeneca <AZN.L> is fully on track to reach its earnings goal for next year, its chief executive told Reuters on Friday after the British drugmaker's quarterly earnings missed market expectations.

* ASTRAZENECA CEO SAYS OVERALL HAVE NOT SEEN DISRUPTION IN OPERATIONS IN CHINA - CONF CALL

UK blue-chip shares slipped further on Friday, weighed down by underwhelming results from AstraZeneca and RBS, while investors remained unsettled due to concerns over the impact of the coronavirus on the global economy.

* ASTRAZENECA - ALL GUIDANCE ASSUMES UNFAVOURABLE IMPACT FROM CHINA LASTING UP TO A FEW MONTHS AS A RESULT OF RECENT NOVEL CORONAVIRUS OUTBREAK

AstraZeneca expects 2020 revenue growth in the high single-digit to low double-digit percentages, including a hit it now expects from the coronavirus outbreak in China, its second biggest market, the British drugmaker said on Friday.

* RECEIVED $3 MILLION FROM ASTRAZENECA AFTER SUCCESSFUL DOSING OF FIRST PATIENT IN PHASE1 CLINICAL TRIAL OF AZD0466 IN DEC Source text https://reut.rs/2OJaYua Further company coverage:

U.S. drugmaker AbbVie's <ABBV.N> $63 billion tie-up with Allergan <AGN.N> is getting help from Nestle <NESN.S> and AstraZeneca <AZN.L> buying up products the Irish-domiciled company is shedding to placate regulators.

AstraZeneca said on Monday it will discontinue a late-stage trial for heart disease drug Epanova to treat patients with mixed dyslipidaemia and expects a $100 million writedown to hit its core profit in the fourth quarter.

AstraZeneca said on Monday it will discontinue a late-stage trial for Epanova to treat patients with mixed dyslipidaemia at high risk of cardiovascular disease and expects a $100 million writedown to hit its core profit in the fourth quarter.

AstraZeneca and Merck's ovarian cancer drug Lynparza has received U.S. regulatory approval for the treatment of advanced pancreatic cancer, cementing its lead in a niche category of cancer treatments.

Dec 30 - AstraZeneca Plc and Merck & Co's ovarian cancer drug, Lynparza, was approved by U.S. regulators for the treatment of advanced pancreatic cancer in patients with BRCA gene mutations, the British drugmaker said on Monday.

(This Dec.20 story corrects first paragraph to say the approval came four months ahead of schedule, not three months, after FDA clarification)

An experimental cancer drug developed by AstraZeneca and Daiichi Sankyo kept metastatic breast cancer at bay for months in women who had exhausted other treatment options, its first clinical study showed.

AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer.

British drugmaker AstraZeneca Plc said on Friday its immunotherapy cancer treatment Imfinzi has been granted a speedy review by the U.S. medicines watchdog for the treatment of a particularly aggressive type of lung cancer.

British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.

British drugmaker AstraZeneca Plc said on Friday its cancer drug Imfinzi has been granted a speedy review by the U.S. Food and Drug Administration (FDA) for the treatment of a particularly aggressive type of lung cancer.

AstraZeneca <AZN.L> shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie <ABBV.N>.